Potential role of pregabalin in the treatment of episodic breathlessness
Letter to the Editor | Symptom Management in Palliative Medicine and Palliative Care

Potential role of pregabalin in the treatment of episodic breathlessness

Jan Gaertner1,2^, Klaus K. Witte3,4^

1Palliative Care Center Basel, Basel, Switzerland; 2Department of Clinical Research, University of Basel, Basel, Switzerland; 3Department of Cardiology, Angiology and Critical Care (Medical Clinic 1), University Hospital RWTH Aachen, Aachen, Germany; 4Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

^ORCID: Jan Gaertner, 0000-0002-1176-3164; Klaus K. Witte, 0000-0002-7146-7105.

Correspondence to: Jan Gaertner, MD. Palliative Care Center Basel, St. Alban Ring 151, 4002 Basel, Switzerland; Department of Clinical Research, University of Basel, Basel, Switzerland. Email: jan.gaertner@pzhi.ch.

Comment on: Schloesser K, Bergmann A, Eisenmann Y, et al. Interaction of panic and episodic breathlessness among patients with life-limiting diseases: a cross-sectional study. Ann Palliat Med 2023;12:900-11.

Submitted Sep 18, 2023. Accepted for publication Oct 30, 2023. Published online Nov 24, 2023.

doi: 10.21037/apm-23-547

We congratulate Schloesser and co-workers on their insightful cohort study assessing the prevalence, perception and role of panic in episodic breathlessness (1). They show elegantly that breathlessness episodes mostly have a duration of under 10 minutes [median: 7.0; standard deviation (SD): 2.1] but those sufferers rate their impairment due to the episodes as high [8.3 on numerical rating scale (NRS) 10 with SD of 1.5 (NRS: 0= no impairment at all, 10= worst imaginable impairment)]. Notably, only 2% of patients reported not having panic during the episode whereas 35% suffered from panic disorder or panic syndrome. Experiencing panic outside the breathlessness episodes correlated significantly with panic intensity during breathlessness episodes (r=0.527, P≤0.001). Their primary study (2), which took the form of a longitudinal observational cohort study revealed that cognitive behavioural therapy (CBT) improved symptomatic status and quality of life which led to their conclusions that this could be a useful adjunct to other treatments in a palliative care setting.

Yet not all patients nor centres have CBT available to them. And based upon the surprising recent data on opiates in heart failure, we should approach tailored care for symptoms in people with a variety of incurable diseases in the same way that we would for any other setting, namely based upon data from randomised controlled studies carried out in a pathway of care informed by observational data. Perhaps rather than targeting the symptoms themselves, we should also consider targeting the anxiety that contributes and exacerbates them. Whether this should be with a medical or non-medical intervention or a combination of both requires further study.

For example, one potential agent could be pregabalin, a potent anxiolytic widely used and highly effective against panic disorder in patients with short and frequent breathlessness episodes. Although published data are limited, we have experience of it is potential in both cancer and non-cancerous conditions such as chronic airways disease, heart failure and pulmonary hypertension. It is particularly effective when there is a large overlay of anxiety.

We propose that future studies should include both objective and subjective endpoints and must be large enough to help determine which intervention (or combination of interventions) is best for which setting. The work by Schloesser provides a solid foundation for including CBT as one of the interventions that require testing, but if we are to help our future patients, it is time to cast the net wide and to do so within a pathway of care that includes multiple potential targets to improve quality of life. To our knowledge this is the first mention of pregabalin for the treatment of anxiety in the context of episodic breathlessness in patients with chronic incurable disease.


Funding: None.


Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://apm.amegroups.com/article/view/10.21037/apm-23-547/coif). J.G. serves as an unpaid Associate Editor of Annals of Palliative Medicine from February 2022 to January 2024. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


  1. Schloesser K, Bergmann A, Eisenmann Y, et al. Interaction of panic and episodic breathlessness among patients with life-limiting diseases: a cross-sectional study. Ann Palliat Med 2023;12:900-11. [Crossref] [PubMed]
  2. Schloesser K, Bergmann A, Eisenmann Y, et al. Only I Know Now, of Course, How to Deal With it, or Better to Deal With it: A Mixed Methods Phase II Study of a Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness. J Pain Symptom Manage 2022;63:758-68. [Crossref] [PubMed]
Cite this article as: Gaertner J, Witte KK. Potential role of pregabalin in the treatment of episodic breathlessness. Ann Palliat Med 2024;13(1):200-201. doi: 10.21037/apm-23-547

Download Citation